Clinical Trial Update: Cardiac Compass With Optivol® to Negate Future Inpatient Re-admissions Through Monitoring in HF Patients (CONFIRM-HF)

View source ↗

Summary

A clinical trial evaluating Cardiac Compass with Optivol to prevent inpatient readmissions in heart failure patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Cardiac Compass with Optivol

Snippet

Sponsor: Thomas Jefferson University | Conditions: Heart Failure | Status: WITHDRAWN